1. Home
  2. LPTX vs KEQU Comparison

LPTX vs KEQU Comparison

Compare LPTX & KEQU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • KEQU
  • Stock Information
  • Founded
  • LPTX 2011
  • KEQU 1906
  • Country
  • LPTX United States
  • KEQU United States
  • Employees
  • LPTX N/A
  • KEQU N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • KEQU Medical Specialities
  • Sector
  • LPTX Health Care
  • KEQU Industrials
  • Exchange
  • LPTX Nasdaq
  • KEQU Nasdaq
  • Market Cap
  • LPTX 119.6M
  • KEQU 106.0M
  • IPO Year
  • LPTX N/A
  • KEQU N/A
  • Fundamental
  • Price
  • LPTX $0.38
  • KEQU $36.30
  • Analyst Decision
  • LPTX Buy
  • KEQU
  • Analyst Count
  • LPTX 2
  • KEQU 0
  • Target Price
  • LPTX $8.00
  • KEQU N/A
  • AVG Volume (30 Days)
  • LPTX 321.1K
  • KEQU 5.9K
  • Earning Date
  • LPTX 08-11-2025
  • KEQU 06-25-2025
  • Dividend Yield
  • LPTX N/A
  • KEQU N/A
  • EPS Growth
  • LPTX N/A
  • KEQU 102.06
  • EPS
  • LPTX N/A
  • KEQU 5.90
  • Revenue
  • LPTX N/A
  • KEQU $220,026,000.00
  • Revenue This Year
  • LPTX N/A
  • KEQU N/A
  • Revenue Next Year
  • LPTX N/A
  • KEQU N/A
  • P/E Ratio
  • LPTX N/A
  • KEQU $6.22
  • Revenue Growth
  • LPTX N/A
  • KEQU 9.44
  • 52 Week Low
  • LPTX $0.22
  • KEQU $30.33
  • 52 Week High
  • LPTX $4.79
  • KEQU $71.33
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 46.09
  • KEQU 42.93
  • Support Level
  • LPTX $0.38
  • KEQU $36.36
  • Resistance Level
  • LPTX $0.44
  • KEQU $40.39
  • Average True Range (ATR)
  • LPTX 0.04
  • KEQU 1.46
  • MACD
  • LPTX -0.00
  • KEQU -0.40
  • Stochastic Oscillator
  • LPTX 22.52
  • KEQU 0.00

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

Share on Social Networks: